Big Pharma's 2030 Patent Cliff: A Framework For Reading What Comes Next

DISCLAIMER: This is independent research and personal commentary. It is not financial or medical advice. EverLife Capital is a publication of Consult US, LLC. It is not a registered investment advisor, broker-dealer, fund, or capital manager. The 25-Gate Research Framework referenced throughout is an analytical methodology, not an investment strategy. Nothing here is a recommendation to buy or sell any security. References to patents, acquisitions, and mechanisms are for discussion purposes only. The technologies described are early-stage research concepts, often based on animal or cellular studies, that may never result in approved therapies. Investing in early-stage biotech is highly speculative and involves substantial risk including total loss of capital. Always consult a qualified financial and medical professional before making any investment or health decision. Full disclosures here.

The pharma patent cliff refers to the loss of market exclusivity on blockbuster drugs as their core patents expire. When that happens, generic and biosimilar competitors enter the market, and revenue often declines substantially after generic or biosimilar entry, though erosion varies by drug class, geography, and competition. Between 2026 and 2030, the pharmaceutical industry faces one of the largest patent cliffs in pharmaceutical history, with reported industry estimates of approximately $236 billion in annual revenue at risk across major manufacturers (some sources estimate the total exposure as high as $400 billion globally through the end of the decade). Companies facing these cliffs typically respond through a combination of internal R&D, licensing, partnerships, and acquisitions. Understanding how the pharmaceutical industry's strategic priorities reshape in response is the subject of this article.

When I sold the servicing operations of CuraDebt earlier this year, some might say I got lucky. I built that business over 24 years without thinking deliberately about who the eventual buyer would be or what they specifically needed. The deal worked. But looking back, I could see that if I had known from the beginning what acquirers valued most - their exact gaps, their strategic priorities, the metrics they cared about - I could have built more deliberately toward that outcome. More deliberately. With fewer wasted years.

I was lucky. I do not want to rely on luck again.

That lesson has been sitting in the back of my mind as I think about longevity biotech analysis. And recently it clicked in a new way. What if you applied the same logic here? Instead of finding promising science and then hoping a buyer eventually shows up, start with the buyer. Map their specific gaps. Understand what they need over the next five to ten years. Then look for science that fills exactly those gaps.

Then overlap that with the L-45 filter — mechanisms that would matter for a healthy 45+ year old if they worked — and you get a smaller, more interesting set. A dual interest in sector progression and personal healthspan, evaluated through the same lens.

That is what this article is about. The framework itself. Specific company evaluations using this framework live in separate articles I'll link at the end.

Between now and 2030, the pharmaceutical industry faces one of the largest patent cliffs in pharmaceutical history. Specific facts that are public record:

Companies facing these cliffs often respond through a combination of internal R&D, licensing, partnerships, and acquisitions. That is the consistent pattern across prior cliffs. The 2025 M&A record gives further signal as to where strategic acquirers are focusing. Among the largest pharma acquisitions announced in 2025 were neuroscience-focused deals including J&J's reported $14.6 billion for Intra-Cellular Therapeutics and Novartis's reported $12 billion for Avidity Biosciences (announced October 2025; completed February 2026). Novo Nordisk announced a reported deal worth up to $5.2 billion for Akero Therapeutics and its MASH candidate ($4.7 billion upfront plus contingent value rights). Cardiometabolic and brain.

Strategic alignment does not imply acquisition probability, clinical success, commercial success, or investment merit.

The broad strategic priorities are increasingly visible. The analytical question is: what science aligns with those areas of strategic interest, has real preclinical data behind it, and also passes the L-45 filter?

The most significant exclusivity losses across the patent cliff window, based on publicly available patent and exclusivity data:

2025 (already lost):

2026 (expected):

2028 (expected):

2026-2030 (additional exposures):

Note: Specific patent expiration dates vary by jurisdiction and may differ between U.S. and ex-U.S. markets. Patent litigation, settlements, and regulatory exclusivity extensions can also shift the practical date of generic or biosimilar entry. Verify against primary sources before relying on any specific date for analysis.

The 25-Gate Research Framework evaluates longevity biotech companies across scientific, regulatory, capital, and competitive dimensions. For this kind of macro analysis, I add one lens up front — the buyer lens — and it changes the shape of the results.

The buyer lens asks: which large pharmaceutical company might consider acquiring this in five to ten years, why specifically, and what would need to be true between now and then for that decision to make sense? That is the CuraDebt lesson. Understand what the strategic buyer needs before you spend years building toward it.

The L-45 filter runs in parallel. It asks: if this science translated to humans, would it matter for a healthy person in their 40s or 50s focused on extending healthspan? Not a disease treatment for someone already sick. A mechanism that addresses biological aging itself. Something that would show up in biomarkers. Something personal.

When a mechanism satisfies both filters - clear potential industry relevance and genuine L-45 relevance - that overlap is where the dual interest of this publication lives. Sector progression that may lead to commercial outcomes for the underlying companies, and mechanisms that may extend personal healthspan if they translate. Whether both happen in any specific case is unknown. The overlap is where the scientific and commercial questions become especially interesting.

If you are 45 or older, the patent cliff conversation is interesting from a sector perspective and the underlying biology is interesting from a personal one. The biological processes being researched in this sector - neuroinflammation, cardiac fibrosis, cellular senescence, mitochondrial decline - are running in your body now, at measurable rates. The potential benefit window for any intervention narrows with time.

If you have built something in your career, you bring the analytical pattern recognition to evaluate this seriously. You have lived through technology cycles. You know what real regulatory pathways look like compared to wishful thinking. This is the reader this publication is written for.

I am 52. I track my biological age. The L-45 filter is not abstract for me, which is part of why this framework exists.

The framework above is a way of reading the sector. The work of applying it to specific companies happens in separate evaluations.

The pattern is consistent: every company that gets evaluated through the 25-Gate Research Framework gets scored against scientific validity, management quality, capital adequacy, mechanism class, strategic partnership potential, endpoint validation, competitive moat, and approximately eighteen additional criteria covering regulatory pathway, IP position, capital structure, competitive landscape, and other dimensions. The L-45 filter runs alongside, asking whether the mechanism would matter for a healthy 45+ year old if it translated.

Companies that clear those filters and reach the Hypothetical Research Tracker have made it through deliberate, methodology-driven evaluation, not pattern-matching on enthusiasm. Companies that get added to the Watch List instead of the Tracker are explicit about what would need to change for the evaluation to update.

That is the work. Macro framing like this article sets up the lens. The individual company evaluations apply it.

Here is what I keep coming back to.

When I sold CuraDebt's servicing operations, I got lucky. The deal worked because someone needed what I had built, but I had not built it with that buyer in mind from the start. I built, then hoped the right acquirer would show up.

That is backwards. And it is also how most early biotech research gets funded. Most founders build from the science outward. They have a mechanism. They find capital that believes in the mechanism. They run clinical trials. Years later they hope a pharmaceutical company decides the data is compelling enough to acquire them.

Some of that works. A lot of it does not. Most early-stage programs ultimately fail, though a small number eventually become commercially significant.

What I am trying to do differently with this publication is start from the other direction. Start with where the industry's priorities are visible. Map what those priorities suggest about the science worth following. Then filter that through the L-45 lens to make sure it is also relevant to the thing that matters most to me personally — healthy lifespan.

When both overlap, the subset becomes more analytically interesting. A mechanism with both potential industry relevance and a personal biological reason to follow it closely. Whether any specific mechanism translates to either outcome is unknown. Most early-stage biology does not. The few mechanisms that ultimately succeed often appear more understandable in retrospect. The challenge is evaluating them carefully while the science is still developing.

If you have built something in your career and want to read why this sector may be worth studying carefully, see An Open Letter To Successful Business Owners Over 45 — a companion piece to this article.

The pharma patent cliff is the loss of market exclusivity on blockbuster drugs as their core patents expire. When this happens, generic and biosimilar competitors enter the market, and revenue often declines substantially after generic or biosimilar entry, though erosion varies by drug class, geography, and competition. The period from 2026 to 2030 represents one of the largest patent cliffs in pharmaceutical history, with industry estimates of approximately $236 billion in annual revenue at risk across major manufacturers including Merck, Bristol Myers Squibb, Novartis, J&J, AbbVie, and Pfizer (some sources estimate the total exposure as high as $400 billion globally through the end of the decade).

Major exclusivity expirations across the 2026-2030 window include: Keytruda (Merck, December 2028), Eliquis (BMS, EU exclusivity 2026 with U.S. generic entry April 2028), Opdivo (BMS, 2028), and Entresto (Novartis), which began facing U.S. generic competition in 2025 following adverse litigation outcomes and ongoing patent disputes. J&J, AbbVie, and Pfizer also face significant exclusivity losses across this window.

Companies losing exclusivity often expand internal R&D and acquisition activity in areas aligned with future strategic priorities. Both late-stage assets and earlier-stage assets in prioritized areas - neuroscience, cardiometabolic, oncology, immunology - are typically part of the response. The 2025 M&A record reflects both patterns.

The L-45 filter asks whether a mechanism would matter for a healthy 45+ year old if it translated to humans. It distinguishes mechanisms that target aging biology itself from mechanisms that treat already-established disease. The filter is one of the screening criteria within the broader 25-Gate Research Framework used at EverLife Capital.

Merck's Keytruda loses its core U.S. patent in December 2028. The drug had roughly $29 billion in 2024 sales and is widely reported among the world's top-selling drugs. After patent expiration, revenue often declines substantially as biosimilar competitors enter the market, though erosion varies by drug class, geography, and competition. Merck has signaled both internal R&D and acquisition activity in oncology and other areas to address the post-Keytruda revenue gap.

Bristol Myers Squibb's Eliquis (apixaban), a $14 billion+ anticoagulant, loses EU exclusivity in the second half of 2026. In the U.S., the compound patent expires September 14, 2026, but generic entry is expected April 2028 following a 2021 patent litigation ruling that upheld BMS and Pfizer's key formulation patent. Eliquis is one of two major products (along with Opdivo) representing a large fraction of BMS's current revenue.

Bristol Myers Squibb's Opdivo loses U.S. exclusivity in 2028. Combined with Eliquis (EU exclusivity 2026, U.S. generic entry April 2028), BMS faces substantial pipeline replacement pressure across the 2026-2028 window.

Novartis's Entresto, a $7.8 billion heart failure drug, faced U.S. generic competition beginning in 2025 after adverse litigation outcomes, despite continuing patent disputes. The development represents a significant gap in Novartis's cardiovascular franchise that is part of the broader strategic context for the 2025 M&A pattern, which saw the largest pharma deals concentrated in neuroscience and cardiometabolic.

Earlier versions of this analysis used "dual ROI" framing. The publication has since adopted more careful language. The dual interest is in (a) sector progression that may lead to commercial outcomes for underlying companies, and (b) mechanisms that may extend personal healthspan if they translate. Whether either occurs in any specific case is unknown. The framing is analytical, not return-predictive.

The framework is described in detail in Frameworks Beat Emotion: How EverLife Capital's Framework Has Evolved. Subscribe to receive ongoing methodology notes, sector analyses, and individual company evaluations.

You'll receive:

Reply to any email. I read every one.

Eric Pemper developed the 25-Gate Research Framework after years of work evaluating longevity biotech companies across mechanism classes. He writes for the 45+ reader whose interest in the sector is both analytical and personal — the dual interest of sector progression and individual healthspan. He sold the servicing operations of CuraDebt in early 2026 after 24 years building the business. He holds personal equity in Repair Biotechnologies and Yuva Biosciences as disclosed above.

Eric Pemper
Consult US, LLC
EverLife Capital

This publication is impersonal and not tailored to the investment needs of any specific person.